Stopping or continuing diabetes medicine before heart surgery
Part of Heart & circulation clinical trials.
This trial tests whether patients with heart failure having heart surgery should stop taking their SGLT-2 inhibitor (like empagliflozin or dapagliflozin) or keep taking it, to see which is safer and better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for heart surgery that uses a heart-lung machine.
- You have been taking an SGLT-2 inhibitor (such as empagliflozin or dapagliflozin) for at least 4 weeks, possibly with metformin.
- You have heart failure with a reduced pumping function (ejection fraction below 50%).
- You do not have severe kidney problems (eGFR less than 25).
- You can understand and speak French, and you have health insurance or equivalent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
This trial tests whether a diabetes medication called dapagliflozin helps smooth out blood sugar swings after bariatric (weight-loss) surgery. It may help people with type 2 diabetes achieve better control after their surgery.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.